





   Promiscuous scaffolds in proteins - non-native,
 non-additive and non-trivial [version 2; peer review: 1 approved
with reservations, 2 not approved]
Sandeep Chakraborty ,       Bjarni Asgeirsson , Mouparna Dutta , Anindya S Ghosh ,
       Masataka Oda , Adela Rendón , Felix Goñi , Jean-Marie Frere ,





















1,8 2 3 3
































 27 Nov 2013,  :260 (First published: 2
)https://doi.org/10.12688/f1000research.2-260.v1
 20 Jan 2014,  :260 (Latest published: 2
)https://doi.org/10.12688/f1000research.2-260.v2
v2
Page 1 of 16
F1000Research 2014, 2:260 Last updated: 22 SEP 2019
 
 Sandeep Chakraborty ( )Corresponding author: sanchak@gmail.com
 No competing interests were disclosed.Competing interests:
 The author(s) declared that no grants were involved in supporting this work.Grant information:
 © 2014 Chakraborty S  . This is an open access article distributed under the terms of the  ,Copyright: et al Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Chakraborty S, Asgeirsson B, Dutta M   How to cite this article: et al. Promiscuous scaffolds in proteins - non-native, non-additive and
 F1000Research 2014,  :260 (non-trivial [version 2; peer review: 1 approved with reservations, 2 not approved] 2
)https://doi.org/10.12688/f1000research.2-260.v2
 27 Nov 2013,  :260 ( ) First published: 2 https://doi.org/10.12688/f1000research.2-260.v1
Page 2 of 16
F1000Research 2014, 2:260 Last updated: 22 SEP 2019
Introduction
Primitive life presumably had minimal gene content and a minus-
cule arsenal of enzymes at its disposal. Unfettered from selection 
pressures by gene duplication, a few select enzymes gained new 
advantageous functions1–3. Nonetheless, the vestiges of second-
ary activities under neutral drift4 possess the potential to reemerge 
under changing selection pressures5,6. This ability of an enzyme 
to catalyze diverse activities using the same active site, termed as 
promiscuity, is the cornerstone of the evolution of complex organ-
isms from pristine life7. In the human context, compound promis-
cuity plays a major role in drug discovery, and in the therapeutic 
efficacy of drugs8. Databases are a crucial medium of cataloging 
known aspects of drug promiscuity9,10.
Ever since Jensen emphasized the role of promiscuity or ‘substrate 
ambiguity’ in evolution through ‘fortuitous error and gain of mul-
tistep pathways’, promiscuity in proteins has been the subject of 
intense and detailed research7. It was demonstrated in 1976 that 
replacing the zinc metal ion by copper in Carboxypeptidase A intro-
duced oxidase catalysis properties11. Dioxygenases promiscuously 
hydrolyse esters12, while the enolase superfamily is also known to 
catalyze numerous catalytic reactions13,14. Alkaline phosphatases 
(AP), one of the key proteins in our research, are one of the most 
widely researched promiscuous enzymes15. APs are known to 
have sulfate monoesterase, phosphate diesterase, and phosphonate 
monoesterase activities16–18. A phosphite-dependent hydrogenase 
activity was also found in Escherichia coli AP (ECAP), but was 
absent in APs from other organisms19. Interestingly, proteins from 
the AP superfamily show cross activity - Pseudomonas aeruginosa 
arylsulfatase (PAS) which has the primary activity of hydrolyz-
ing sulfate monoesters also catalyzes the hydrolysis of phosphate 
monoesters20,21.
The evolution of species through sequence mutations leaves a trail 
via the conservation of fragments or repeats that have been honed 
to achieve specific functions with remarkable efficiency22–24. The 
sequence-to-structure-to-function paradigm facilitates the functional 
characterization of new proteins by applying a ‘guilt by associa-
tion’ logic, and has essentially revolutionized the field by its easy 
to use model25. However, occasionally nature achieves the same 
solution to an enzymatic problem through a completely different 
sequence, arriving at the same spatial conformation required for 
catalysis. For example, the catalytic Ser-His-Asp triad has virtu-
ally the same geometry in the major families of serine proteases 
(chymotrypsin and subtilisin), which have no sequence or structural 
homology26 - a classical example of convergent evolution27,28. Such 
convergently evolved proteins, and those redesigned from chiseled 
scaffolds through exon shuffling, remain beyond the scope of 
sequence analysis methods. As such structure-based methods have 
evolved to detect such relationships29,30. The choice of methods for 
binding site comparisons and methods for binding site detection as 
well as function prediction has been recently reviewed in detail31. 
Notably, most of these methods are based on structural properties 
of the binding or the active site. We have demonstrated that such 
a structural conservation leading to the same function necessi-
tates the conservation of electrostatic properties as well (CLASP - 
www.sanchak.com/clasp)32. The ability of finite difference methods 
to quickly obtain consistent electrostatic properties from peptide 
structures provides an invaluable tool for investigating other innate 
properties of protein structures33. Furthermore, using a database of 
known active sites in proteins (http://www.ebi.ac.uk/thornton-srv/
databases/CSA/34), we have proposed a methodology to quantify 
promiscuity in a wide range of proteins35.
In an endeavor to establish the validity of the computational 
predictions made by CLASP, we have undertaken several in vitro 
initiatives using different enzymes. The results of these experiments 
have provided several insights regarding promiscuous functions in 
proteins. Foremost amongst them is corroboration of the intuitive 
notion that inhibition is inherently simpler to predict than true catalysis. 
For example, we detected the presence of the serine protease (SPASE) 
catalytic triad motif (Ser195, His57, Asp102) in alkaline phosphatases 
(AP) from various organisms using the spatial and electrostatic con-
gruence, and validated this by inhibition of the native phosphatase 
activity using inhibitors (AEBSF/PMSF)32, known to be active on 
many serine proteases by reaction with the nucleophilic serine36. 
However, true SPASE activity was limited to shrimp AP. Recently, 
the crown domain in the E. coli expressed rat intestinal AP protein 
was shown to be prone to protease cleavage, which the authors have 
ascribed to self-cleavage37. Another recent review nicely summarizes 
the various computational approaches applied to the AP superfamily 
in order to gain insights into the promiscuous functions observed 
in proteins belonging to the superfamily15. The therapeutic potential 
of AP inhibitors has also seen increased interest from medicinal 
researchers38.
In a similar experiment, we detected a SPASE motif in a phospho-
inositide-specific phospholipase C (PI-PLC) from Bacillus cereus 
using CLASP39. Once again, although we easily established the 
inhibition of the native activity of PI-PLC using serine protease 
inhibitors, we struggled to establish proteolysis based on known 
protease substrates. Fortuitously, we observed protease activity 
of PI-PLC on UVI31+, a protein under investigation in our group 
for different reasons40. We thus concluded that one should exert 
caution before ruling out protease activity in an enzyme since theo-
retically proteases have a large number of possible substrates due 
to the possible variation in residues flanking the sissile bond, and 
the corresponding folds that harbor a recognition site for a particular 
protease39. Thus, it is possible that we have not found the ideal 
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proteolytic substrate for APs32. We also tested the proteolytic 
functions and inhibition using protease inhibitors of the non-toxic 
B. cereus phosphatidylcholine-specific phospholipase C (PC-PLC) 
and the closely related highly toxic Clostridium perfringens α-toxin 
(CPA) (which possesses an additional C-terminal domain demon-
strated to be responsible for its sphingomyelinase, hemolytic, and lethal 
activities41,42). CPA and PC-PLC activities on phospholipids were unaf-
fected by the addition of serine protease inhibitors in concurrence 
with the CLASP analysis which fails to detect a SPASE scaffold 
in these proteins39. While CPA and PC-PLC did have a metallo-
protease motif based on CLASP analysis, and both showed protease 
activity in vitro, the observed proteolytic activity can be attributed 
as an artifact of a metallo-protease contamination which is diffi-
cult to remove in spite of the purification steps. Inhibition of CPA 
activity using a metallo-protease inhibitor was tried out, but failed 
to show any results. Such lack of inhibition by a single compound is 
not sufficient ground to rule out the existence of a metallo-protease 
scaffold.
Based on predictions from CLASP, we also demonstrated the inhibi-
tion of the native phosphatase activity of a cold active alkaline phos-
phatase from Vibrio strain G15-21 AP (VAP)43 by a specific β-lactam 
compound (only imipenem, and not by ertapenem, meropenem, 
ampicillin or penicillin G)44. CLASP analysis detected a spatial 
and electrostatic congruence of the active site of a Class B2 CphA 
metallo-β-lactamase (MBL) from Aeromonas hydrophila45 to the 
active site of VAP. Several β-lactam compounds failed to inhibit 
E. coli or shrimp AP, as was expected by the lower congruence 
indicated by CLASP as compared to VAP. While all APs contain 
three metal ion binding sites essential for catalysis43, MBLs have 
either one or two metal binding sites46. It would be interesting to 
imagine the existence of a protein (possibly evolved from VAP) that 
is an MBL and requires three metal binding sites.
Another desired aspect in the search of promiscuous motifs is the 
ability to search for partial scaffolds, as has been implemented in 
the DECAAF methodology47,48. The search for an elastase-like 
motif in a plant protein47 led us to the pathogenesis-related pro-
tein P14a49. Although the complete motif was missing - stated 
previously as, ‘While Ser195, His57, and Gly193 from the input motif 
have a highly matching scaffold in P14a, the spatial position of 
the elastase Asp102 is close to Asn35 and Ser39 in P14a when 
the proteins are superimposed based on the matching scaffolds48’ 
- the structural similarity of the P14a protein to a snake venom 
protein with a known elastase function50 suggested strongly the 
possibility of pre-existing elastase functionality, or indicated 
a fair chance of endowing elastase activity through directed 
evolution techniques.
Another fascinating aspect of enzymes, although strictly not defined 
as promiscuity, is their ability to catalyze the reaction of a range 
of similar substrates of the same class51. We have hypothesized 
that duplicate residues, each of which results in slightly modified 
replicas of the active site scaffold, are responsible for the broad 
substrate specificity of proteins52,53.
It might appear that the presence of a motif like a SPASE catalytic 
triad in a protein structure is trivial, and one could expect any ran-
domly chosen protein with a large number of residues to have such 
a structural motif. However, the absence of a spatially congruent 
SPASE catalytic triad in a reasonably large tyrosine phosphatase 
CD45 (PDBid: 1YGR, sequence length 610) highlights the fact 
that the SPASE motif is not present ubiquitously (Table 1). Even 
the presence of a spatially congruent motif, as in the human trans-
lation initiation factor (PDBid: 2E9H), does not imply potential 
congruence (Table 1).
The biggest challenge in detecting promiscuous motifs is to be able 
to endow the function using rational steps54–56. However, the non- 
additive nature of active site residues makes this a non-trivial task 
even when a very close partial match exists57. For example in a 
catalytic site consisting of n residues, the existence of a congruent 
n − 1 motif does not imply that it is easy or even possible to add 
another residue in the structure and obtain the n residue motif. This 
complexity is best exemplified in the failure to induce β-lactamase 
activity in a penicillin-binding protein (PBP-5) from E. coli58,59 by 
generating the L153E mutant of this protein, as proposed by our previous 
analysis47 (unpublished results). Although many directed evolution 
experiments have tried to enhance deacylation in PBPs60, 61, the catalytic 
step that β-lactamases use to hydrolyze β-lactams62, very few have 
Table 1. Non-triviality of the potential and spatial congruence of the active site residues in 
proteins from the serine protease motif. The serine protease catalytic triad has been taken from 
a non-psychrophilic trypsin from a cold-adapted fish species (PDBid: 1A0J). The reasonably large 
tyrosine phosphatase CD45 (PDBid: 1YGR, sequence length 610) does not contain the spatially 
congruent catalytic triad. Although, a motif spatially congruent to the catalytic triad is present in the 
human translation initiation factor (PDBid: 2E9H), it lacks electrostatic potential congruence. D = Pairwise 
distance in Å. PD = Pairwise potential difference. SLen = sequence length. APBS writes out the electrostatic 
potential in dimensionless units of kT/e where k is Boltzmann’s constant, T is the temperature in K and e is 
the charge of an electron.
PDB Active site atoms(a,b,c) ab ac bc SLen
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been successful. Even the successful attempts have reported low 
gains in β-lactamase activity (110-fold in60 and 90-fold in61).
In spite of the inherent difficultly in rationally designing proteins, 
we believe that the fast maturing field of protein structure prediction 
might soon allow us to quickly iterate over in silico mutations63. 
A method like CLASP may be used to discriminate the predicted 
structures in order to select the mutations that achieve the desired 
congruence with a reference scaffold - setting up the flow to mimic 
the natural ‘evolutionary walk’ in vitro, and accelerate this ‘random 
walk’ into a ‘resolute sprint’.
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The commentary by Chakraborty  focuses on the important topics of understandinget al.
and modeling enzyme promiscuity, and raises some intriguing points about the
importance of local electrostatic effects (beyond structure alone) on enzyme activity.
However, the commentary is quite tightly focused on protease-type activity in different
scaffolds, and even more so on the authors own work. This manuscript would be
improved by providing more context on how their previous work relates to other studies
of AP promiscuity/polyspecificity (including in particular the work of the Herschlag and
Hollfelder groups) and electrostatic approaches to enzyme mechanism (Warshel, Houk,
and many others). This would broaden the potential audience for this commentary, which














Moving on to specifics, I am unconvinced by the use of protease inhibitors as a test of
bona fide protease activity in several of the works discussed. The fact that a particular
compound inhibits an enzyme does not necessarily mean that it resembles a substrate, or
that the enzymes mode of action resembles that of the compounds other targets.
We agree that inhibition does not “not necessarily mean that it resembles a substrate, or that the
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On the other hand, as the authors acknowledge, the absence of inhibition by a particular
compound is not enough to demonstrate the lack of a particular activity or functional
motif. These assays thus have significant risks of both false positives and false negatives,
and these should be explicitly discussed.
This is something we should touch upon. We thank you for pointing this out.
 
What we are left with are apparently observations of protease activity both by enzymes
predicted to have SPASE activity (shrimp and E. coli APs, and PI-PLC) and by those
predicted to lack it (PC-PLC and CPA) unfortunately, not very strong evidence for the







In Table 1, it is not clear what 1A0J is.
We have fixed this in version 2 (the other reviewer has pointed this out too).
 
Also, it is not clear what the criteria are for either spatial or potential congruence. More
broadly, it is difficult to assess the frequency of SPASE-compatible triads in proteins in
general from just 3 examples. Is it feasible for the authors to estimate the frequency of
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We have argued in favor of both these points throughout our work. “This invariance in the
electrostatic features (measured in structures that have been solved independently over many
years) is an innate property required for the enzymatic activity. This also speaks highly of the




Page 12 of 16





This commentary reads more like a review and only describes work previously performed
by the researchers. I have a number of reservations about this previously published work.
The authors should present more detail from at least one example where dual activity has
.been proven
We have explicitly stated in the abstract that we intend to ‘discuss insights gained in several
’. Thus, this would not qualify as a review sinceinitiatives using our method on different enzymes
we do not consider the work of those researchers whose work we have built upon.
 
Can the authors supply any explanation for the presence of a serine peptidase activity in
alkaline phosphatase from a shrimp, but not ? If there was anyEscherichia coli
physiological relevance for the peptidase activity for an alkaline phosphatase then surely
it would be con- served. It seems extraordinarily serendipitous that the authors are
working on UVI31+ and that this is the only substrate for the peptidase activity of shrimp
alkaline phosphatase the authors could detect. This is unlikely to be a physiological
substrate, which implies that the serine peptidase activity of alkaline phosphatase is very
general, and it is behaving as if its role was protein degradation rather than limited
processing. Given that there are so many other peptidases for recycling proteins - the
proteasome in the cytoplasm, lysosomal pepti-dases, digestive enzymes of the stomach
and gut, for example - what would be the evolutionary pressure to maintain such a
generalized function for alkaline phosphatase? Have the alleged serine peptidase activity
of shrimp alkaline phosphatase, and the alleged inhibition of alkaline phosphatase activity




presence of auto cleavage in these alkaline phosphatases - “the loss of crown domain due to















- “A phosphite-dependent hydrogenase activity was also found in ECAP, but was absent in APs
[ ]”. Another example is the inhibition of VAP using imipenem, which doesfrom other organisms 19
not inhibit ECAP.
 
I can  understand  that  a  small  molecule  like  PMSF  might  block  any  active  site 
serine, regardless of the type of enzyme, but the authors claim that the protein
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serine, regardless of the type of enzyme, but the authors claim that the protein
ovoinhibitor reduces alkaline  phosphatase  activity,  which  would  require  not  only  an 
active  site  but  also  at  least one substrate binding site for the reactive site in the





Why were synthetic substrates not used instead of proteins? Then proper kinetics could
be measured, rather than presenting bands on a gel.
We did try out many synthetic substrates, but we could not find any protease activity. However we
have not yet tried the Pro-Xxx that would duplicate the bond in UVI31+ cleaved by PI-PLC. We
believe that ‘one should exert caution before ruling out protease activity in an enzyme since
theoretically proteases have an innumerable number of possible substrates due to the infinite




Clearly the authors are aware of the dangers of contamination, because they admit to
having had problems with a metallopeptidase contaminating phospholipase C, for which




The controls that the authors use in their experiments, namely to denature all proteins
with SDS, would not address this problem, because any contaminant would be denatured
as well as the enzyme under experimentation. Use of peptidase inhibitors would be
equally useless if the catalytic type of the contaminating peptidase and the enzyme in





Perhaps the authors should abandon commercial preparations and use recombinant







The authors state that their CLASP analysis is unable to find a serine peptidase-like active
site in phospholipase C, and that this  is  confirmed  by  failure  to  inhibit  phospholipase 
C with a serine peptidase inhibitor. This is an example of a negative result proving a
negative hypothesis, which really doesn’t prove anything.
There has been some misunderstanding - we mention ‘CPA and PC-PLC activities on
phospholipids were unaffected by the addition of serine protease inhibitors in concurrence with the
’. This is expected, sinceCLASP analysis which fails to detect a SPASE scaffold in these proteins
they are metallo proteins. CLASP does find the serine peptidase-like active site in PI-PLC, which
we go on to confirm through in vitro experiments [39].
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In Table 1, the structure 1A0J should be described in the legend.
We have made the correction, thank you.
 
Promiscuity in enzyme active sites is a known phenomenon. An example that comes to
mind is leukotriene A4 hydrolase, which not only hydrolyses the epoxide but also acts as
an aminopeptidase using the same active site. There are also numerous examples where
an active site performs different functions in different organisms (or even in the same
organism for some protein products of paralogous genes): for example proteins with the 
alpha/beta  hydrolase fold, where some are peptidases and some are lipases. It would
strengthen the authors’ case considerably to include examples such as these before
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